Effects of Various Treatment Regimens on the Survival of HER2-positive Breast Cancer Patients with Brain Metastasis

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Overexpression of HER2 (human epidermal growth factor receptor 2) occurs in around 20% of breast cancers. This particular subtype is known to be very aggressive and had the worst prognosis prior to the introduction of targeted therapy. The development of anti-HER2 therapies such as trastuzumab and pertuzumab has shown to dramatically improve the prognosis of patients with HER2-positive breast cancer.

Related collections

Author and article information

Journal

Title: The Physician

Abbreviated Title: Phy

Publisher: British Association of Physicians of Indian Origin

ISSN (Electronic): 2732-5148

ISSN (Print): 2732-513X

Publication date Created: April 28 2020

Publication date (Electronic): November 27 2019

Volume: 6

Issue: 1

Page: c12

Article

DOI: 10.38192/1.6.1.c12

SO-VID: cfdfcb5c-5510-4002-b4f2-dccbb68d0d65

License:

https://creativecommons.org/licenses/by-nc-nd/4.0

History

Data availability:

Comments

Comment on this article

scite_